A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma https://www.biorxiv.org/content/10.1101/2023.09.12.557334v1

A new study from @pmresearch-uhn.bsky.social shows that combining two drugs (enasidenib with venetoclax) can help people with hard-to-treat #AcuteMyeloidLeukemia achieve remission.

This offers hope for longer remissions and easier outpatient care.

🔗 Read more: www.uhnresearch.ca/news/promisi...

Very excited to share that that the Myelomatch study I am leading is open to accrual! We are investigating ASTX727 +/- enasidenib in higher-risk IDH2m MDS

clinicaltrials.gov/study/NCT065...

A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma https://www.biorxiv.org/content/10.1101/2023.09.12.557334v1

New study shows oral combo of enasidenib + venetoclax helps 62% of patients with IDH2 mutated, relapsed or refractory #AML achieve remission. Safe, effective, and outpatient-friendly. Led by our Drs. Steven Chan & Guillaume Richard-Carpentier.
@thelancethaem.bsky.social:
doi.org/10.1016/S235...

#tandem25 #leusm Chen: Enasidenib maintenance is well tolerated after allo, but of unclear benefit from Ph1 data.

Clinical studies have demonstrated that Enasidenib can lead to durable remissions and significant reductions in leukemic cells.
#Enacitib50Mg #Enasidenib #IebPharma #AntiCancer #AntiViral #BreastCancer #KidneyCancer #LiverCancer
iebpharma.com/product/lenv...

#chemdle 284
mechanism of not today's chemical
pyridine C2 lithiation
doi: 10.1021/acs.jmedchem.9b00196, p.7536, synthesis of enasidenib

(RCM) LC/Q‐TOF‐MS‐based structural characterization of enasidenib degradation products and establishment of a stability‐indicating assay method: Insights into chemical stability: Rationale

Enasidenib (EDB) is an orally active selective… http://dlvr.it/T1XlH4 #RapidCommunMassSpectrom #MassSpecRSS

Enasidenib plus venetoclax shows activity in relapsed or refractory IDH2-mutated AML
sohoinsider.com/leukemia/ena...

The Drug is C, Idhifa (enasidenib), an antineoplastic that treats acute myeloid leukemia. Alvadore, Chiloquin, and Neotsu are cities or towns in Oregon, USA. Did you know? Thanks for playing the Name Game. There is a different one every night.

🎥 Jennifer Marvin-Peek of @mdanderson.bsky.social shares the results of a Phase I/II study evaluating an all-oral triplet regimen combining decitabine, venetoclax, & ivosidenib or enasidenib in IDH1-/IDH2-mutated AML:

👉 buff.ly/Z3WVJCU 👈

#SOHO2025 #AMLsm #Leusm #Leukemia #CTSM #TrialUpdate #HemOnc

#myeloMATCH sub-study MM1OA-S03 is open!
Patients registered to MYELOMATCH screening protocol who are 60+ or unfit for chemo and have AML w an IDH2 gene mutation may be assigned. Randomized to venetoclax + ASTX727 w/wo enasidenib.
swog.org/clinical-trials/MM1OA-S03 @beatalleukemia.bsky.social